Avnish Patel
About Avnish Patel
Avnish Patel serves as the Head of Compounding at HeliosX Group, where he has worked since 2020. He has a diverse background in pharmaceutical research and education, including roles at Syngenta, GSK, and London Metropolitan University.
Current Role at HeliosX Group
Avnish Patel serves as the Head of Compounding at HeliosX Group, which includes Dermatica and MedExpress. He has held this position since 2020, contributing to the development and management of compounding processes within the organization. His role involves overseeing the formulation of personalized medications, ensuring compliance with regulatory standards, and enhancing the overall quality of pharmaceutical products.
Previous Experience at Syngenta
Before joining HeliosX Group, Avnish Patel worked at Syngenta as a Senior Research Scientist from 2018 to 2020. During his tenure, he focused on research and development projects aimed at improving agricultural products. His work contributed to advancements in the field, leveraging his expertise in pharmaceuticals and compounding.
Educational Background in Pharmaceutics
Avnish Patel obtained his Doctor of Philosophy (PhD) in Pharmaceutics from University College London (UCL), where he studied from 2012 to 2016. His academic background provided him with a strong foundation in pharmaceutical sciences, which he has applied throughout his career in various roles within the industry.
Experience in Academia and Research
In addition to his industry roles, Avnish Patel has experience in academia. He served as an Associate-Guest Lecturer at London Metropolitan University in 2018 for four months. He also worked as a Postdoctoral Research Associate at UCL from 2017 to 2018, where he engaged in advanced research projects that further developed his expertise in pharmaceutical sciences.
Pharmacy Training and Early Career
Avnish Patel began his career in pharmacy as a Pre-registration Pharmacist at Dartford & Gravesham NHS Trust from 2011 to 2012. He completed his Master of Pharmacy at the University of London from 2007 to 2011, which laid the groundwork for his subsequent roles in research and compounding within the pharmaceutical industry.